1. Home
  2. FFWM vs ORKA Comparison

FFWM vs ORKA Comparison

Compare FFWM & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FFWM
  • ORKA
  • Stock Information
  • Founded
  • FFWM 1990
  • ORKA 2004
  • Country
  • FFWM United States
  • ORKA United States
  • Employees
  • FFWM N/A
  • ORKA N/A
  • Industry
  • FFWM Major Banks
  • ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • FFWM Finance
  • ORKA Health Care
  • Exchange
  • FFWM Nasdaq
  • ORKA Nasdaq
  • Market Cap
  • FFWM 378.0M
  • ORKA 354.2M
  • IPO Year
  • FFWM 2014
  • ORKA N/A
  • Fundamental
  • Price
  • FFWM $5.14
  • ORKA $11.74
  • Analyst Decision
  • FFWM Buy
  • ORKA Strong Buy
  • Analyst Count
  • FFWM 4
  • ORKA 8
  • Target Price
  • FFWM $7.25
  • ORKA $39.71
  • AVG Volume (30 Days)
  • FFWM 542.7K
  • ORKA 156.9K
  • Earning Date
  • FFWM 07-24-2025
  • ORKA 08-15-2025
  • Dividend Yield
  • FFWM N/A
  • ORKA N/A
  • EPS Growth
  • FFWM N/A
  • ORKA N/A
  • EPS
  • FFWM N/A
  • ORKA N/A
  • Revenue
  • FFWM $113,564,000.00
  • ORKA N/A
  • Revenue This Year
  • FFWM $182.35
  • ORKA N/A
  • Revenue Next Year
  • FFWM $7.79
  • ORKA N/A
  • P/E Ratio
  • FFWM N/A
  • ORKA N/A
  • Revenue Growth
  • FFWM N/A
  • ORKA N/A
  • 52 Week Low
  • FFWM $4.42
  • ORKA $5.49
  • 52 Week High
  • FFWM $8.52
  • ORKA $52.32
  • Technical
  • Relative Strength Index (RSI)
  • FFWM 48.56
  • ORKA N/A
  • Support Level
  • FFWM $4.98
  • ORKA N/A
  • Resistance Level
  • FFWM $5.53
  • ORKA N/A
  • Average True Range (ATR)
  • FFWM 0.17
  • ORKA 0.00
  • MACD
  • FFWM -0.02
  • ORKA 0.00
  • Stochastic Oscillator
  • FFWM 39.83
  • ORKA 0.00

About FFWM First Foundation Inc.

First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.

About ORKA Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: